Filtered By:
Condition: Antiphospholipid Syndrome
This page shows you your search results in order of date. This is page number 11.
Order by Relevance | Date
Total 523 results found since Jan 2013.
Moyamoya Syndrome Presenting with Ischemic Stroke Caused by Rapid Worsening of Vessel Stenosis Associated with Triple-seropositive Antiphospholipid Syndrome: A Case Report
Intern Med. 2022 Aug 10. doi: 10.2169/internalmedicine.9316-22. Online ahead of print.ABSTRACTSeveral case reports of patients with both moyamoya syndrome (MMS) and antiphospholipid syndrome (APS) have been published. However, the relationship between MMS and APS has not been clarified. We herein report a patient with MMS who had an ischemic stroke with rapid worsening of stenosis of the middle cerebral artery associated with APS. The patient was triple-positive for antiphospholipid antibodies. Patients with MMS complicated by APS should be closely followed up with vascular imaging.PMID:35945020 | DOI:10.2169/internalmedicine.9316-22
Source: Internal Medicine - August 9, 2022 Category: Internal Medicine Authors: Kazumasa Oura Takashi Yamaguchi Taro Suzuki Mao Yamaguchi Oura Ryo Itabashi Tetsuya Maeda Source Type: research
A novel aGAPSS-based nomogram for the prediction of ischemic stroke in patients with antiphospholipid syndrome
ConclusionAge, diabetes, hyperuricemia, the platelet count, and the aGAPSS were risk factors for IS in patients with APS. The aGAPSS-IS may be a good tool for IS risk stratification for patients with APS based on routinely available data.
Source: Frontiers in Immunology - July 29, 2022 Category: Allergy & Immunology Source Type: research
A Cryptogenic Stroke Associated With Infective Endocarditis and Antiphospholipid Antibody Syndrome: Case Report and Literature Review
ConclusionA considerable challenge for physicians is evaluating all the signs suggestive of embolic sources in acute stroke and identifying the primary etiology when there are multiple causes. Early diagnosis and surgical intervention for bicuspid aortic valve (BAV) vegetation complicated by acute stroke may yield favorable clinical results.
Source: Frontiers in Neurology - July 25, 2022 Category: Neurology Source Type: research
Causes of ischemic stroke in young adults versus non-young adults: A multicenter hospital-based observational study
CONCLUSIONS: Certain embolic sources and uncommon causes may be etiologically important causes of ischemic stroke in young adults. However, the contribution of conventional vascular risk factors and lifestyle-related risk factors is not negligible with advancing age, even in young adults.PMID:35830430 | DOI:10.1371/journal.pone.0268481
Source: Atherosclerosis - July 13, 2022 Category: Cardiology Authors: Yuichiro Ohya Ryu Matsuo Noriko Sato Fumi Irie Kuniyuki Nakamura Yoshinobu Wakisaka Tetsuro Ago Masahiro Kamouchi Takanari Kitazono Investigators for Fukuoka Stroke Registry Source Type: research
Severe Libman –Sacks endocarditis complicating antiphospholipid syndrome: a retrospective analysis of 23 operated cases
ConclusionSevere HVD leading to surgery was strongly associated with thrombotic APS, especially arterial phenotypes. Half of the reported patients presented cerebral stroke complicating the HVD. Valvular surgery carried a significant risk of CAPS.
Source: Rheumatology - June 10, 2022 Category: Rheumatology Source Type: research
Disability and cognitive impairment are interdependent in primary antiphospholipid syndrome
CONCLUSIONS: Disability in PAPS and CI are interdependent. New treatment options and neurocognitive stimulation strategies are necessary to maintain functionality and prevent further cognitive dysfunction in PAPS patients.PMID:35657275 | DOI:10.1177/09612033221106647
Source: Lupus - June 3, 2022 Category: Rheumatology Authors: Gabriela Medina Erik Cim é-Aké Raquel Bonilla-V ázquez Olga Vera-Lastra Miguel Ángel Saavedra Mar ía Pilar Cruz-Domínguez Luis J Jara Source Type: research
New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news
